Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Update

Atossa Genetics Inc. (NASDAQ:ATOS) was the target of a large decrease in short interest in February. As of February 13th, there was short interest totaling 408,724 shares, a decrease of 91.3% from the January 29th total of 4,696,759 shares. Based on an average daily volume of 311,677 shares, the short-interest ratio is currently 1.3 days. Approximately 5.2% of the shares of the stock are short sold. Approximately 5.2% of the shares of the stock are short sold. Based on an average daily volume of 311,677 shares, the short-interest ratio is currently 1.3 days.

Analyst Ratings Changes

Several research analysts recently issued reports on ATOS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, January 21st. Ascendiant Capital Markets lifted their price target on Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $95.00.

Atossa Genetics Stock Up 1.4%

Atossa Genetics stock opened at $4.27 on Thursday. The company has a market capitalization of $36.76 million, a PE ratio of -1.19 and a beta of 1.36. The firm has a fifty day simple moving average of $7.82 and a two-hundred day simple moving average of $10.94. Atossa Genetics has a twelve month low of $3.76 and a twelve month high of $19.35.

Hedge Funds Weigh In On Atossa Genetics

Hedge funds and other institutional investors have recently modified their holdings of the company. &PARTNERS purchased a new stake in Atossa Genetics in the 4th quarter worth approximately $25,000. Hudson Bay Capital Management LP bought a new position in Atossa Genetics in the 2nd quarter worth $26,000. Gallagher Capital Advisors LLC purchased a new stake in shares of Atossa Genetics in the 3rd quarter worth about $27,000. JPMorgan Chase & Co. lifted its position in shares of Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after purchasing an additional 35,474 shares during the period. Finally, Catalyst Funds Management Pty Ltd bought a new stake in shares of Atossa Genetics during the 2nd quarter valued at about $49,000. 12.74% of the stock is owned by institutional investors.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.